NCT05363670View on ClinicalTrials.gov

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions
Asthma
Interventions
DRUG

ARS-1

ARS-1

DRUG

Albuterol MDI

180 mcg

DRUG

Placebo

Placebo

Trial Locations (4)

20815

Institute for Asthma and Allergy, Chevy Chase

33613

University of South Florida, Tampa

45236

Bernstein Clinical Research Center, LLC, Cincinnati

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

ARS Pharmaceuticals, Inc.

INDUSTRY